GlassScriptPhysician profile
Heather D Bryce
NPI 1982729588
$8,072.20
in general payments reported to CMS, 2019-2025
30 companies · $2,057 in 2025
The $2,057 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $873 · 2022: $1,653 · 2023: $1,983 · 2024: $1,506 · 2025: $2,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,545 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,545.19 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,940.34 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,470.80 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $730.17 | 2022-2025 | |
| Lilly USA, LLC | $583.30 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $560.83 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $287.47 | 2021-2024 | Veozah, Myrbetriq |
| Lundbeck LLC | $244.65 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $178.22 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.96 | 2024-2025 | Caplyta |
| Sk Life Science, INC. | $170.74 | 2023-2024 | Xcopri |
| Otsuka America Pharmaceutical, INC. | $160.45 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $160.22 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $144.19 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.59 | 2021-2025 | Jardiance, Synjardy |
| Inspire Medical Systems, INC. | $122.55 | 2023 | Inspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $121.88 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $120.52 | 2022-2025 | Freestyle Libre 3 |
| Alkermes, INC. | $118.11 | 2024 | Lybalvi |
| Axsome Therapeutics, INC. | $117.72 | 2025 | Auvelity |
| Ucb, INC. | $112.46 | 2021 | |
| Sanofi-Aventis U.S. LLC | $83.84 | 2024-2025 | |
| Corium, LLC | $78.48 | 2023 | Azstarys |
| Sumitomo Pharma America, INC. | $75.66 | 2023-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $42.44 | 2023 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $32.28 | 2024 | Ingrezza |
| Dexcom, INC. | $27.57 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $19.64 | 2024 | |
| Intra-Sana Laboratories | $18.72 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Pfizer INC. | $18.41 | 2025 | |
| Aimmune Therapeutics, INC. | $17.99 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Bryce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.